A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Sponsor: Alnylam Pharmaceuticals
You may qualify if…
- ✓ Has HCC confirmed histologically or cytologically, or, for patients with liver cirrhosis, clinically by the American Association for the Study of Liver Diseases (AASLD) criteria
- ✓ Has had at least one line of systemic therapy for unresectable advanced or metastatic disease
- ✓ Has at least one wingless-related integration site (WNT)-pathway activating mutation
- ✓ Child-Pugh class A or B7
You may not qualify if…
- ✕ Has fibrolamellar HCC, sarcomatoid HCC, or mixed cholangio-HCC tumors
- ✕ Has symptomatic extrahepatic disease
- ✕ Has received anti-cancer therapy or investigational drugs ≤3 weeks prior to the first dose of study drug
- ✕ Note: other protocol defined inclusion / exclusion criteria apply
Where it's recruiting
Source: ClinicalTrials.gov · NCT06600321 · last updated 2026-06-17